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Posttranscriptional gene regulation by miRNAs and
RNA binding proteins (RBP) is important in develop-
ment, physiology, and disease. To examine the inter-
play between miRNAs and the RBP ELAVL1 (HuR),
we mapped miRNA binding sites at the transcrip-
tome-wide scale in wild-type and Elavl1 knockout
murine bone-marrow-derived macrophages. Prox-
imity of ELAVL1 binding sites attenuated miRNA
binding to transcripts and promoted gene expres-
sion. Transcripts that regulate angiogenesis and
macrophage/endothelial crosstalk were preferen-
tially targeted by miRNAs, suggesting that ELAVL1
promotes angiogenesis, at least in part by antago-
nism of miRNA function. We found that ELAVL1
antagonized binding of miR-27 to the 30 UTR of
Zfp36 mRNA and alleviated miR-27-mediated sup-
pression of the RBP ZFP36 (Tristetraprolin). Thus,
the miR-27-regulated mechanism synchronizes the
expression of ELAVL1 and ZFP36. This study pro-
vides a resource for systems-level interrogation of
posttranscriptional gene regulation in macrophages,
a key cell type in inflammation, angiogenesis, and
tissue homeostasis.
INTRODUCTION
In multicellular eukaryotes, posttranscriptional gene regulatory
mechanisms are critical for coordinating complex cellular
behavior during development, homeostasis, and disease (Chang
and Hla, 2011; Chekulaeva and Filipowicz, 2009; Farazi et al.,
2011; Keene, 2007). Recent work has highlighted the essential
roles played by microRNAs (miRNAs) and RNA binding proteins
(RBPs) that interact with the cis-regulatory elements of tran-
scripts to regulate gene expression (Ciafre` and Galardi, 2013).
Among the RBPs, ELAVL1 (also known as HuR) is ubiquitously
expressed and binds to AU-rich element (ARE)- and U-rich
element (URE)-containing mRNAs (Abdelmohsen et al., 2007).
ELAVL1 has been implicated in the regulation of cell cycle, cell2330 Cell Reports 9, 2330–2343, December 24, 2014 ª2014 The Autmigration, tumorigenesis, apoptosis, immunity, inflammation,
and angiogenesis (Abdelmohsen and Gorospe, 2010; Gorospe
et al., 2011; Katsanou et al., 2009). Indeed, ELAVL1 expression
is elevated in cancers of the breast, ovary, colon, and brain (Den-
kert et al., 2006; Vo et al., 2012) and associated with poor prog-
nosis (Abdelmohsen and Gorospe, 2010; Wang et al., 2013).
ELAVL1, located primarily in the nucleus, is translocated into
the cytoplasm upon cellular perturbation and returns back into
the nucleus (Abdelmohsen et al., 2007). ELAVL1 function is impli-
cated in gametogenesis (Levadoux-Martin et al., 2003), placental
development (Katsanou et al., 2009), and stem/progenitor cell
survival (Ghosh et al., 2009). In macrophages, ELAVL1 regulates
inflammatory and angiogenic processes (Zhang et al., 2012).
miRNAs are small RNAs of 21–24 nt that associate with Argo-
naute (Ago) proteins in the RNA-induced silencing complex
(RISC) and bind to partially complementary sites predominantly
located in the 30 UTR of target mRNAs. RISC binding leads to
repression of target gene expression by deadenylation and
subsequent mRNA destabilization and/or translational repres-
sion (Chekulaeva and Filipowicz, 2009; Fabian et al., 2010).
Recent work suggests dynamic regulation of miRNA-mediated
gene silencing, including cooperative/antagonistic interactions
with RBPs, such as ELAVL1, PUM1, and DND1. For example,
let-7b/c binding to the 30 UTR of c-Myc was strongly induced
when ELAVL1 binds to a nearby ARE site (Kim et al., 2009).
In contrast, ELAVL1 binding to the CAT-1 (cationic amino
acid transporter 1) 30 UTR blocks the miR-122 binding on the
CAT-1 mRNA, allowing the exit of the CAT-1 mRNA from cyto-
plasmic processing bodies (P bodies) to induce expression of
the CAT-1 protein (Bhattacharyya et al., 2006). Further, ELAVL1
and miR-200b antagonistically regulate Vegfa and angiogenesis
in murine macrophages (Chang et al., 2013). PUM1 binding to a
canonical site in the 30 UTR of the p27 (Cdkn1b) mRNA exposes
a miRNA binding site and allowed miR-221/-222-mediated
suppression of this critical cell-cycle regulator (Kedde et al.,
2010). In contrast, DND1 was found to antagonize the inter-
action of miR-221/222 with p27 mRNA, miR-430 with Nos1
mRNA (Kedde et al., 2007), and miR-21 with Msh2 (Bhandari
et al., 2013). These studies indicate that miRNA suppression
of gene expression is regulated by RBPs. Transcriptome-wide
characterization of miRNA/RBP interaction has not been
reported.hors
A B
C
Figure 1. AGO2 PAR-CLIP Experiments in
BMDMs Identify ELAVL1-Regulated miRNA
Binding Sites
(A) Experimental outline for AGO2 PAR-CLIP in
BMDMs. WT and Elavl1 KO BMDMs were labeled
with 4-thiouridine (4-SU), and the PAR-CLIP ex-
periments and bioinformatic pipeline are sche-
matically represented. See also Figure S1.
(B and C) Distribution of PAR-CLIP binding sites
[total sites (B) and high-read PAR-CLIP sites (C)]
were determined by aligning the PARalyzer results
with the mouse MM9 genome.A high-throughput method called photoactivatable ribonucle-
oside-enhanced crosslinking and immunoprecipitation (PAR-
CLIP) was developed recently that provided ameans to precisely
define binding sites of miRNAs and RBPs with their target tran-
scripts at the global scale (Hafner et al., 2010a, 2010b; Lebedeva
et al., 2011). To gain a comprehensive understanding of ELAVL1-
mediated modulation of miRNA/mRNA interaction sites in
macrophages, we performed AGO2 PAR-CLIP experiments in
wild-type (WT) and Elavl1 knockout (KO) bone-marrow-derived
macrophages (BMDMs). We combined these data with miRNA
and mRNA expression profiling to provide a global view of
miRNA/ELAVL1 regulatory networks in vivo. From this, we found
that, in macrophages, genes that regulate angiogenesis and
blood vessel development were highly targeted by miRNAs
and ELAVL1. In addition, we identified a mechanism by which
ELAVL1 controls the expression of ZFP36, a major RBP that
destabilizes ARE-containing transcripts, thus achieving homeo-
stasis of the ARE-containing transcriptome.
RESULTS
PAR-CLIP Reveals the Global Landscape of ELAVL1-
Dependent miRNA Targets in Bone-Marrow-Derived
Macrophages
In order to define miRNA/mRNA interaction sites at the global
scale, and to examine regulation of these sites by ELAVL1,
we conducted AGO2 PAR-CLIP analysis in pooled BMDMs
(108 cells) isolated fromWT (Elavl1f/f) andmacrophage-specific
Elavl1 KO (Elavl1f/f LysM-Cre) mice. The outline of AGO2 PAR-
CLIP experiments is described in Figure 1A.
PARalyzer was used to map reads to the mouse genome
(mm9) and identify groups of overlapping reads, which represent
AGO2 binding sites on the transcriptome (Corcoran et al., 2011).
Approximately 3.5 3 106 reads from WT and Elavl1 KO of the
sequence data sets met our criteria and were further analyzed.Cell Reports 9, 2330–2343, DeIn total, we obtained 25,500 clusters
representing predicted AGO2 binding
sites from both WT and Elavl1 KO. PAR-
CLIP sites are most frequently associated
with 30 UTRs (52%), followed by coding
regions (20%), intergenic (17%), and in-
tronic (7%) regions (Figure 1B). Further,
more than 58% of high-depth PAR-CLIP
sites (>100 reads; 5,362 sites) are in the30 UTR (Figure 1C). We also searched the PAR-CLIP 30 UTR sites
for the presence of G-rich element, which was purported to
represent AGO2 binding sites on transcripts independently of
miRNAs (Leung et al., 2011). However, the occurrence of
G-rich element was lower than random chance, suggesting that
30 UTR PAR-CLIP sites are likely to be primarily targeted by the
RISC complex and were further analyzed as described below.
Characterization of the miRNome, Transcriptome,
and Mapping Transcriptome-wide miRNA Binding Sites
Next, we quantified miRNA expression levels by RNA sequenc-
ing in BMDMs of WT and Elavl1 KO mice and identified 211 ex-
pressed miRNA species (Table S1). Only five miRNAs showed
more than 2-fold alteration in expression upon Elavl1 deletion
(Figure S2). We performed a similar analysis on the PAR-CLIP
data set to identify AGO2-associated miRNA species and quan-
tified their relative abundance (Figure 2A), which revealed signif-
icant differences of miRNAs in this population with that of
total miRNAs. However, differential crosslinking efficiency could
result in erroneous abundance assignment in this population
of miRNAs. Therefore, we used the total miRNA abundance
data in the assignment of particular species of miRNAs to
PAR-CLIP sites.
We also characterized the BMDM transcriptome by mRNA
sequencing (mRNA-seq) analysis. Sequencing analysis from
WT and Elavl1 KO samples detected 11,033 mRNA species ex-
pressed in BMDMs (reads per kilobase of transcript per million
reads mapped [RPKM]R0.1) (Table S2). Only 14 of the mRNAs
exhibited R2-fold change (p < 0.05). This data set contains
8,043 transcripts that were also present in the PAR-CLIP data
set. Among those, 12,323 miRNA binding sites in the 30 UTR
region of 4,145 transcripts were mapped.
In order to identify high-confidence miRNA binding sites, we
selected PAR-CLIP sites with high reads (R100) in 30 UTR
sequences. As shown (Figure S3), 3,033 sites out of 25,000cember 24, 2014 ª2014 The Authors 2331
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Figure 2. Transcriptome-wide View of ELAVL1 Regulation of miRNA Binding Sites in BMDMs
(A) miRNA sequencing profile of total miRNAs and PAR-CLIP miRNAs in WT and Elavl1 KO BMDMs. Colored sections indicate top ten highly expressed miRNA.
(B) The Circos plot shows transcriptome-wide view of mRNA levels and miRNA binding activity on transcripts. Results are presented as the ratio between Elavl1
KO/WT. The outer circle indicated the position of chromosomes 1–19 and sex chromosomes. The middle circle represents mRNA expression determined by
RNA-seq experiments. Log2 relative change for transcripts that have more than 0.1 RPKM inmRNA sequencing (mRNA-seq) (11,033 genes) is shown (n = 4). The
innermost track shows the ratio (KO/WT) of log2 relative reads of top 1,000 PAR-CLIP sites at 3
0 UTRs. Color code is as above.
(C and D) ELAVL1 depletion affects gene expression via interactions with miRNA binding sites on transcripts. (C) Among the transcripts with a predicted ELAVL1
site near miRNA binding sites (R100 PAR-CLIP reads/site), those in which miRNA binding is increased in the KO (R2-fold) showed decreased expression
(red line). In contrast, genes with decreased miRNA binding (KO/WT %0.5, blue line) showed no change in expression level. (D) Among the transcripts with
no predicted ELAVL1 site near miRNA binding sites (R100 PAR-CLIP reads/site), even when miRNA binding is increased (KO/WT R2, red line) or decreased
(KO/WT <0.5, blue line), there was no significant change in expression.sites meet our stringent criteria, which is PAR-CLIP sites with
R100 combined reads and >98% sequence overlap at the
binding site between WT and Elavl1 KO. Using this data set,
the transcriptome-wide representation of miRNA binding sites
and the associated mRNA expression profiles are represented
in the Circos plot (Figure 2B). Significant number of miRNA
binding sites showed altered binding strength in Elavl1 KO
BMDMs; 466 (15.36%) showed reduction and 432 (14.24%)2332 Cell Reports 9, 2330–2343, December 24, 2014 ª2014 The Autshowed increase (±2-fold or more). However, corresponding
mRNAs did not show similar degree of changes in expression.
Indeed, very few (0.03%) of the high miRNA-bound transcripts
showed greater than 2-fold change in expression in the
absence ELAVL1.
We categorized 3,033 sites into two groups based on the dis-
tance between AGO2 binding sites and ELAVL1 consensus
sites. In the first group of transcripts in which AGO2 bindinghors
site and ELAVL1 consensus site are %30 nt (total number =
1,309), increased miRNA binding significantly correlated with
reduced mRNA expression (Figure 2C, red line). However, tran-
scripts with decreased miRNA binding did not change mRNA
expression levels (Figure 2E, blue line). In contrast, transcripts
containing AGO2 binding site without or >30 nt (total number =
1,724) away from ELAVL1 binding site did not show any changes
in mRNA expression levels regardless of miRNA binding (Fig-
ure 2D). These data suggest that ELAVL1 competes with prox-
imal miRNA binding on target mRNAs.
Prediction of miRNA/mRNA Interactions
from the PAR-CLIP Data Set
We annotated PAR-CLIP sites with predicted miRNA target sites
using the TargetScan (TargetScan 6.2) (Lewis et al., 2005).
Approximately 34% of high-confidence PAR-CLIP sites at 30
UTR region were assigned to at least one miRNA by TargetScan.
We noticed that the high-read miRNA binding sites were more
likely to be conserved among species. In addition, conserved
miRNA binding sites with high reads have a high signal- (bona
fide PAR-CLIP signal) to-noise (occurrence of a random 28 nt
fragment from any 30 UTR that contain a TargetScan-predicted
seed region) ratio (Figure 3A, red box). This indicates that our
PAR-CLIP data set is highly correlated with miRNA binding sites
identified by computational methods. We also used seed
sequences from the miRNA list that we identified in BMDMs
(Table S1) to predict miRNA/mRNA binding. Because several
confirmed miRNA target genes contain G:U base pairs or
single-nucleotide bulges, we used 7-mer seed sequence and
allowed one G:U wobble in our prediction. Using this workflow,
we were able to assign at least one miRNA to 87.9% of PAR-
CLIP sites in the 30 UTR region. These predicted miRNA/mRNA
pairs for PAR-CLIP sites are shown in Table S3. If more than
one miRNA was identified by miRNA target prediction, prefer-
ence was given to the more abundant miRNA species.
This analysis identified previously characterized miRNA/
mRNA interactions correctly. For example, the Cdkn1b tran-
script, which encodes the cyclin-dependent kinase inhibitor
p27, showed two tandemmiR-221/222 binding sites (Figure 3B),
which is consistent with previous work (Kedde et al., 2010). We
did not see alterations in miR-221 binding to Cdkn1b transcript
in Elavl1 KO BMDMs. Similarly, miR-27 interaction with the
Mef2c transcript was identified (Figure 3C) (Chinchilla et al.,
2011). For the c-Myc transcript, a major let-7 binding site that
is 11 nt downstream of an ELAVL1 consensus motif was identi-
fied. Let-7 binding was decreased 1.4-fold in Elavl1 KO cells,
suggesting that ELAVL1 binding to the c-Myc mRNA facilitates
let-7/RISC complex binding to the transcript (Figure 3D). This
is analogous to human ELAVL1, which cooperated with the
let-7 miRNA to suppress C-MYC expression (Kim et al., 2009).
To validate miRNA interaction with these transcripts, we immu-
noprecipitated WT and Elavl1 KO BMDM lysates with anti-
AGO2 antibody and examined the amount of mRNAs (Figure 3E).
Cdkn1b,Myc, andMef2c transcripts were associatedwith AGO2
complex and immunoprecipitated mRNA level correlated with
the strength of PAR-CLIP signal. Moreover, AGO2-associated
Myc mRNA was significantly reduced in Elavl1 KO BMDMs,
whereas Cdkn1b and Mef2c mRNAs were unchanged. TheseCell Redata validate our identification of specific miRNA binding sites
and modulation of such interactions by ELAVL1 in BMDMs.
miRNA-Regulated Angiogenic Genes Expression
in BMDMs and Modulation by ELAVL1
We analyzed transcripts that show strong miRNA binding (R200
AGO2 PAR-CLIP reads) by Gene Ontology (GO) analysis to
identify cellular processes that are regulated by miRNA-medi-
ated gene regulation. Using these criteria, we identified 825
and 864 genes from WT and Elavl1 KO, respectively, among
which 712 genes are common (Figure 4A). We performed GO
analysis with 712 genes in the background of 8,019 expressed
genes in BMDMs. The analysis identified blood vessel morpho-
genesis/development, vasculature development, and tube
development/branching (collectively referred to as the angio-
genesis cluster) as highly significant biological processes
(Figures 4B and 4C). In the Elavl1 KO BMDMs, cell-surface-re-
ceptor-linked signal transduction process was identified as
most significant.
Even though miRNA binding of transcripts involved in the
blood vessel development/angiogenesis cluster is modulated
by ELAVL1, steady-state mRNA levels do not show similar
degree of fluctuations (Figure 4D). However, in general, there
appears to be negative correlation between miRNA binding
intensity and transcript expression levels. These data suggest
that ELAVL1 competes with miRNA binding of a subset of
mRNAs and that such interactions influence steady-state
mRNA levels in a reciprocal manner.
The miRNA-targeted transcripts in BMDMs that are involved
in angiogenesis/blood vessel development processes are shown
in Table S4. Transcripts that encode cell-surface receptors
involved in signal transduction, namely, CXC chemokine recep-
tor-4 (Cxcr4), transforming growth factor b (TGF-b) receptor-1
and -2 (Tgfbr1, Tgfbr2), integrin a4 (Itga4), integrin av (Itgav),
VEGF-A coreceptor neuropilin-A (Nrp1), raft-specific protein
caveolin (Cav1), cell-surface phosphatase specific for lipid
lysophosphates (Ppap2b) were targeted by miRNAs. In addition,
transcripts that encode the cell-surface protease Adam8
(Adamts8) and phospholipid binding protein Annexin A2 (Anxa2),
which acts as a cell-surface receptor for tissue-typeplasminogen
activator, were also identified. Transcripts encoding cytosolic
signaling proteins, namely, the heterotrimeric Ga13 protein
(Gna13), small G protein RhoB (Rhob), small GTPase acti-
vating protein Rasa (Rasa), cytoskeletal regulators myosin H9
(Myh9), myosin 1e (Myo1e), Wasf2, signaling kinases - Mapk1,
TGF-b-activated kinase-1 (Map3k7 also known as Tak1), TGF-
b-regulated signaling proteins (Smad5 and Smad7), RNA binding
proteins Quaking (Qk), Zinc finger protein 36-like 1 (Zfp36l1)
and Rbm15, ubiquitin E3 ligase involved in Notch signaling
Mindbomb (Mib1), andBcl-2 familymemberBak1were targeted.
Endoplasmic reticulum (ER)/Golgi-resident proteins, inducible
heme oxygenase (Hmox1), Nogo4 (Rtn4) and sphingosine
1-phosphate lyase (Sgpl1), ER-specific protein (Erap1), and
b-galactosidase (B4galt1) involved in cell-surface glycan compo-
sition were also targeted by miRNAs. Nuclear proteins such as
transcription factors E2F7 (E2f7), hypoxia-inducible factor
(HIF)-1a (Hif1a), myocyte enhancer factor (MEF)2a (Mef2a), myo-
cardin-like (Mkl)-2 (Mkl2), upstream binding protein (UBP)-1ports 9, 2330–2343, December 24, 2014 ª2014 The Authors 2333
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Figure 3. Detection of Constitutive and ELAVL1-Modulated miRNA Binding on 30 UTR
(A) BMDMAGO2 PAR-CLIP sites with high reads contain miRNA binding sites predicted by TargetScan. PAR-CLIP sites were sorted by the number of combined
reads (WT and Elavl1 KO) from high to low and plotted in the x axis. The signal-to-noise ratio on y axis represents the probability of findingmiRNA seed sequences
in the PAR-CLIP sites normalized to the probability of TargetScan prediction of a random 30 UTR sequence of similar length.
(B) miRNA binding sites (PAR-CLIP signals) on Cdkn1b (p27) mRNA 30 UTR. Two conserved miR-221/222 binding sites across human and mouse were reported
on Cdkn1b 30 UTR regions and detected in our PAR-CLIP data with very high reads.
(C) miR-27 binding on Mef2c 30 UTR was reported in mouse embryonic cardiomyocytes and detected in our data set.
(legend continued on next page)
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Figure 4. Gene Ontology Analysis for Bio-
logical Processes Targeted by miRNAs in
WT and Elavl1 KO BMDMs
(A) The Venn diagram shows the number of tran-
scripts with highmiRNA binding (R200 PAR-CLIP/
transcript) on 30 UTR from WT and Elavl1 KO
BMDMs that were used for GO analysis using the
DAVID bioinformatics program. An expressed
gene pool (RPKMR0.1) frommRNA-seq data was
used as the background for GO analysis.
(B) GO analysis identified four categories of GO
terms that were related to blood vessel develop-
ment from the top first GO cluster in common
transcripts (n = 712) that are highly targeted by
miRNAs (FDR, false discovery rate).
(C) Bar plot of GO analysis results for the top ten
GO terms from WT and Elavl1 KO BMDMs. GO
terms that are common with those in (B) shown
above were labeled in red.
(D) Heatmap of mRNA expression level (left panel)
of 44 genes from blood vessel development/
angiogenesis cluster in (B) were compared with
respective total PAR-CLIP signals on the 30 UTR
(right panel).(Ubp1), zinc finger MIZ type containing (Zmiz-1) (Zmiz1), and
b-catenin (Ctnnb1) were targeted bymiRNAs. In addition, TCDD-
inducible poly(A) polymerase (TipArp), an enzyme involved in
RNA metabolism was also targeted. Five of these mRNAs
(E2f7, Hif1a, Mef2a, Pdgfa, and Ppap2b) showed higher miRNA
binding in the absence of ELAVL1, whereas Erap1 and Nrp1
showed reduced targeting of miRNAs in the absence of ELAVL1.
The schematic of biological roles and subcellular localization of
proteins encoded by miRNA-targeted transcripts identified in
BMDMs is shown in Figure 5.
Macrophage Transcripts Involved in Chemotaxis,
Paracrine Interactions with Vascular Cells, and TGF-b
Signaling are Targeted by miRNAs and ELAVL1
Interestingly, miRNA targeting is prominent in macrophage
genes important for migration and chemotaxis. For example,
mRNA encoding integrins a4 and av, chemokine receptor
CXCR4, cell-surface lysophospholipid phosphatase LPP3, het-
erotrimeric Ga13 protein, small GTPase RhoB, small GTPase
regulator Rasa1, Rho kinase Rock2, cytoskeletal regulators
Myosin H9 and myosin 1e, S1P lyase (Sgpl1), and raft-resident
Caveolin-1 proteins were targeted. These genes are involved in
migration of macrophages in response to chemokines and lipid(D) miRNA binding sites on the c-MycmRNA. UCSC genome browser screen shot was annotated with predic
sites are indicated with green bars. Actual ELAVL1 binding sites from previous PAR-CLIP in human HEK293 c
levels in BMDMs were shown as a heatmap in log10 scale.
(E) Validation of miRNA binding to Cdkn1b, Mef2c, and Myc transcripts. WT or Elavl1 KO cell lysates were
G (IgG) or anti-AGO2 antibody and subjected to real-time qRT-PCR to quantify Cdkn1b, Mef2c, and Myc
Gapdh was used as negative control. t test for significance between AGO2 IP and control (IgG), P < 0.01. E
Cell Reports 9, 2330–2343, Demediators as well as extracellular matrix
molecules (Giannice et al., 2013;
Grande-Garcı´a and del Pozo, 2008;
Humtsoe et al., 2010; Lue et al., 2011;Mai et al., 2011; Mao et al., 2013; Rasheed et al., 2013; Wheeler
and Ridley, 2007; Yester et al., 2011).
ThesemRNAswere further examined in detail for miRNA inter-
action sites. In the integrin alpha 4 gene (Itga4) 30 UTR region,
miR-21 binding site at position 2,100 nt is induced 3.6-fold in
the Elavl1 KO BMDMs. Indeed, an overlapping ELAVL1 binding
motif was identified, suggesting that miR-21 and ELAVL1
compete for the expression of ITGA4 polypeptide (Figure 6A).
Similarly, miR-21 binding sites were predicted in the Map3k7 30
UTR (Figure S4A). This site is also located close to the ELAVL1
consensus site and AGO2 PAR-CLIP signal was increased in
the Elavl1 KO BMDMs. These data suggest that multiple tran-
scripts in the macrophage migration pathway are targeted by
miR-21, which are antagonized by ELAVL1 binding to mRNAs.
In the Cav1 30 UTR region, two major miRNA binding sites for
miR-103 and miR-142-3p were predicted (Figure 6B). miR-103
binding site showed strong AGO2 PAR-CLIP signal both in WT
and Elavl1 KO. Interestingly, miR-142-3p binding site where
two potential ELAVL1 binding sites are closely located showed
increased AGO2 PAR-CLIP signal (2.32-fold) in Elavl1 KO
BMDMs. This result suggests that competition of miR-142-3p
and ELAVL1 binding regulates CAV1 expression. In a similar
manner, miR-27b targeting of Tgfbr1 and miR-26a targeting ofted miRNA species (red). Potential ELAVL1 binding
ell are indicated with gray bars. MiRNA expression
immunoprecipitated with control immunoglobulin
transcripts. Hprt was used for normalization, and
rror bars indicate SD.
cember 24, 2014 ª2014 The Authors 2335
Figure 5. Schematic of miRNA-Targeted
Transcripts in BMDMs that Regulate Vessel
Development/Angiogenesis
Twenty-five out of 44 transcripts in the vessel
development/angiogenesis cluster from GO anal-
ysis are depicted schematically to illustrate the
signaling network targeted by specific miRNAs
that are modulated by ELAVL1. Transcripts
labeled in red indicate those in which miRNA
binding in the 30 UTR is antagonized by ELAVL1
(>1.5-fold increase in PAR-CLIP reads in KO).
Those labeled in green indicate that miRNA
binding in the 30 UTR is promoted by ELAVL1
(>1.5-fold decreased in PAR-CLIP reads in KO).
Individual miRNA ID with red and green colors
indicate that miRNA binding sites on 30 UTR was
predicted to this miRNA and showsmore than 1.5-
fold increase or decrease. Those miRNAs indi-
cated in black did not show alterations in WT and
KO BMDMs.Itgav were also antagonized by ELAVL1 in BMDMs (Figures S4B
and S4C). These data suggest that miRNAs regulate the tran-
scripts that encode proteins required for macrophage chemo-
tactic and migratory responses and that these interactions are
regulated by ELAVL1.
Transcripts that regulate paracrine signaling factors between
macrophages and endothelial cells were also targeted by
miRNAs. For example, secreted growth factors, VEGF-A,
PDGF-A, and PDGF-B, and transcription factors that control
their expression, HIF1a, E2F7, and MEF2A, were subject to
miRNA-mediated gene regulation. Interestingly, let-7 was pre-
dicted to target both E2f7 and Hif1a and let-7 binding to the
E2f7 and Hif1a mRNAs was increased in ELAVL1 KO (Figures
S4D and S4E). Because E2f7 can form a transcriptional complex
with Hif1a to stimulate Vegfa transcription (Weijts et al., 2012),
these data suggest that ELAVL1 allows VEGF-A expression by
antagonizing miRNA-mediated repression of transcription fac-
tors for this potent angiogenic factor in macrophages. In addi-
tion, transcript for Mef2a, a transcription factor that regulates
PDGF-B expression (Yablonka-Reuveni and Rivera, 1997) was
found to be targeted by miR-142 family and the binding sites
of miR-142-5p and miR-142-3p was antagonized by ELAVL1
(Figure 6C). Furthermore, mRNAs for paracrine growth factors
themselves, namely, Pdgfa, Pdgfb, and Vegfa, were targeted
by miRNAs, and in particular, mir221/222 that targets Pdgfa
and miR-126-3p that targets Vegfawere affected by Elavl1 dele-
tion (Figures S4F and S4G). These data provide information on
the impact of miRNA and ELAVL1 regulation of macrophage
paracrine angiogenic factor expression and transcription factors
that regulate the expression of such factors.
Our PAR-CLIP data also revealed that components of the TGF-
b signal transductionpathwayare targetedbymiRNAs inBMDMs.
Several studies have indicated that TGF-b receptors and their2336 Cell Reports 9, 2330–2343, December 24, 2014 ª2014 The Authorssignal transduction through Smad family
and MAPK cascade can regulate macro-
phage alternative activation phenotypes
associated with anti-inflammation, wound
healing, and angiogenesis (Koide et al.,2013; Valluru et al., 2011). In our PAR-CLIP data set, Smad5
and Smad7 transcripts were targeted by miR-155 and miR-15/
16, respectively (Figures S5H and S5I), whereas Map3k7 (TAK1)
andMapk1 (ERK) mRNAs were regulated by miR-21 and several
other miRNAs (miR-28a-5p, miR-196, miR-93-5p) (Figure S4A).
Transcripts encoding TGF-b receptors, Tgfbr1 and Tgfbr2, were
targeted by Let-7, miR-142-3p, and miR-93-5p (Figures S4B
and S4J). Interestingly, miR-21 binding to Map3k7 mRNA was
antagonized by ELAVL1, whereas miR-93-5p binding to Tgfbr2
mRNA was cooperative with ELAVL1.
Consistent with the PAR-CLIP data, Itga4, Cav1, and Mef2a
transcripts were associated with AGO2 complex, and the level
of AGO2-enriched Itga4,Cav1, andMef2a transcripts was signif-
icantly induced in Elavl1 KO BMDMs (Figure 6D). Accordingly,
expression of ITGA4, CAV1, and MEF2A polypetides were
reduced in Elavl1 KO cells (Figure 6E). Furthermore, transfection
of miR-142-3p mimic decreased expression whereas inhibition
of miR-142-3p by siRNA increased expression of both CAV1
andMEF2A (Figure 6F). These experiments confirmed of our pre-
diction of miRNA/mRNA interactions.
MiR-142-3p and miR-27 were the most represented in target-
ing the 42 transcripts involved in the angiogenesis cluster. For
example, nine transcripts (Hif1a, Rhob, Tgfbr1, Tiparp, Mef2a,
Itgav, Cav1, Adam8, and Qk) were predicted as the target of
miR-142-3p. Several studies indicate that miR-142-3p is critical
for myeloid development and differentiation and tumor progres-
sion (Saito et al., 2012; Sonda et al., 2013).
ELAVL1 Regulates ZFP36 Expression via a miRNA-
Mediated Regulatory Loop
ZFP36 or tristetraprolin (TTP), a ubiquitously expressed ARE-
binding protein, promotes the decay of mRNAs (Blackshear
et al., 2003). Both ELAVL1 and ZFP36 target the ARE on Zfp36
30 UTR, and ZFP36 autoregulates its own expression through a
negative-feedback loop (Al-Ahmadi et al., 2009). In our AGO2
PAR-CLIP analysis of BMDMs, one of the top 100miRNAbinding
sites with an adjacent/overlapping ELAVL1-binding sequence
was identified in the 30 UTR of Zfp36 mRNA (Figure 7A). This
interaction was increased 1.9-fold in Elavl1 KO BMDMs (Fig-
ure 7B). Two other less prominent PAR-CLIP signals were not
altered by Elavl1 deletion. Expression of the Zfp36 mRNA was
increased 1.26-fold after Elavl1 deletion (Table S2). After
normalization of the mRNA levels, miR-27b binding to the
Zfp36 transcript was increased 1.5-fold in Elavl1 KO BMDMs.
AGO2-associated Zfp36 mRNA was increased in Elavl1 KO
BMDMs (Figure 7C). To test if increased miR-27b binding regu-
lates the ZFP36 protein expression, we transfected miRNA-27b
mimic in BMDMs and measured ZFP36 expression by western
blot analysis. ZFP36 expression in nonstimulated cells was
barely detectable and strongly induced with lipopolysaccharide
(LPS) treatment. As shown in Figure 7D, miR-27b mimic
suppressed30% LPS-induced ZFP36 expression. This sup-
pression was also observed in RAW cells, a mouse macrophage
cell line. These data suggest that Elavl1 antagonizes miR-27b
binding to the 30 UTR of Zfp36mRNA and allows robust expres-
sion of this mRNA instability factor.
To further confirm this model, we measured ZFP36 protein
expression in WT and Elavl1 KO BMDMs. As shown in Figure 7E,
ZFP36 expression level is reduced 50% in Elavl1 KO BMDMs
treated or not with LPS (Figure 7E). The modulation of Zfp36
mRNA levels by LPS treatment was not altered by Elavl1 deletion
(Figure S5A). On the other hand, the expression of miR-27b was
strongly suppressed by LPS between 8 and 24 hr, an effect that
occurred in both WT and Elavl1 KO BMDMs (Figure S5B).
Zfp36 30 UTR-driven luciferase reporter assays showed that
the miR-27b mimic suppressed reporter activity (Figure 7G).
When the miR-27b binding seed region on Zfp36 30 UTR was
mutated, the suppressive effect of miR-27b was lost. Further, if
the ELAVL1 binding sequence near the miR-27b site was
mutated, the suppressive effect of the miR-27b mimic was
more efficient (Figure 7G). These data confirm that miR-27 sup-
pression of ZFP36 expression is antagonized by ELAVL1.
Knockdown of Elavl1 in HEK293T cell by small hairpin RNA
(shRNA) was used to further confirm the interactions between
ELAVL1 and miR-27b (Figure S6). The suppressive effect of
miR-27b was more efficient in Elavl1 knockdown cells (Fig-
ure 7H). Mutation in the ARE1 of the Zfp36 30 UTR resulted in effi-
cient suppression of luciferase activity in both control and Elavl1
knockdown cells in response to miR-27b mimic, further confirm-
ing competitive interactions of miR-27b and ELAVL1 at this site.
In contrast, mutation in the ARE2 did not alter reporter activity of
Zfp36 30 UTR in response to miR-27b mimic. Taken together, we
identified a key regulatory element in the Zfp36 30 UTR and the
competitive interaction of miR-27 and ELAVL1.
DISCUSSION
PAR-CLIP Analysis Allows Systems Level Mapping of
miRNA Binding Sites
In this report, we describe a comprehensive mapping of miRNA
binding sites in murine BMDMs, which have been used exten-Cell Resively in the studies of inflammation, innate immunity, tumor
biology, and angiogenesis. Our primary purpose was to examine
the biology of the RBP ELAVL1, which regulates gene expression
at the posttranscriptional level by binding to ARE and URE se-
quences. ELAVL1 is primarily localized in the nucleus even
though it can be exported to the cytoplasm and shuttles between
the nucleus and the cytoplasm. Because miRNA-mediated gene
suppression is thought to occur primarily in the cytoplasm, our
aim was to comprehensively define modulation of miRNA bind-
ing sites by ELAVL1 using BMDMs that are from WT and Elavl1
KO mice. Our rationale was to define miRNA binding sites
induced or suppressed by ELAVL1 as well as those that are
not affected (Chang et al., 2013). We also developed conditions
to specifically immunoprecipitate endogenous murine AGO2
after crosslinking of the RISC complex. For this approach, we
employed the PAR-CLIP technique that uses 4-SU incorporation
followed by UV-crosslinking and immunoprecipitation (Hafner
et al., 2010b).
Our data set was comprehensive and defined miRNA binding
sites in the BMDM transcriptome with high accuracy. Because
we considered only those sites containing T to C conversion,
the presence of false-positives was minimized (Mukherjee
et al., 2011). Overall, we annotated 3,140 sites in the 30 UTR,
which contain the most (58%) PAR-CLIP sites. PAR-CLIP sites
were also found in coding regions (17%), introns (5%), and
intergenic sites (17%). The roles of such sites are not clear at pre-
sent. In addition, our data set did not contain significant number
of G-rich sequences, which could interact with AGO2 in a
miRNA-independent manner (Leung et al., 2011). This work
complements previous characterization of genome-wide miRNA
binding sites in HEK293, HeLa cells, andmouse and human brain
tissues (Boudreau et al., 2013; Hafner et al., 2010a; Lebedeva
et al., 2011; Mukherjee et al., 2011). However, transcriptome-
wide modulation of miRNA/mRNA interactions by an RBP has
not been described.
ELAVL1/miRNA Interactions on the Transcriptome
To accurately assign miRNA sites on the BMDM transcriptome
and to determine those that are regulated by ELAVL1, we deter-
mined the expression patterns and abundance of miRNA and
mRNA species by RNA sequencing (RNA-seq) analysis of puri-
fied RNA from BMDMs. For miRNA expression characterization,
we compared the data sets from total small RNA preparations as
well as from the PAR-CLIP experiments. RNA-seq analysis indi-
cated thatWT and Elavl1KOBMDMcontains largely similar tran-
script profiles. This was surprising given that ELAVL1 is a major
RNA stabilizing protein that interacts with hundreds to thou-
sands of targets (Lebedeva et al., 2011; Mukherjee et al.,
2011). Indeed, approximately 16% of transcripts in the genome
contain potential ELAVL1 binding sites and PAR-CLIP analysis
using Anti-ELAVL1 antibodies have identified >26,000 sites in
human cells (Lebedeva et al., 2011; Mukherjee et al., 2011). In
our experiments using primary BMDMs, the Elavl1 gene is
deleted by the LysM-Cre nuclease, which is activated early in
the differentiation of the myeloid lineage cells (Chang et al.,
2013). Thus, under steady-state conditions, even though
ELAVL1-mediated RNA stabilization mechanisms were absent,
compensatory mechanismsmay have been activated to balanceports 9, 2330–2343, December 24, 2014 ª2014 The Authors 2337
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Figure 6. Modulation of miRNA Binding Sites on Angiogenic Regulatory Transcripts by ELAVL1
(A–C) UCSCgenomebrowser views of PAR-CLIP data andmRNA-seq data on Itga4 (A),Cav1 (B), andMef2a (C) transcripts. Labeling is similar to Figure 3 (above).
The color code represents log10 scale of average miRNA reads from miRNA-seq data. Green bars represent potential ELAVL1 binding sequences that contain
UUUNUUUor less than 2 A base in 7 poly U region (e.g., UUAUUAUor UAUUUAU). Red-labeledmiRNA ID represent themost likely miRNAs for a given PAR-CLIP
site.
(D) Itga4, Cav1, and Mef2a have higher miRNA binding in Elavl1 KO BMDMs. BMDM lysates were immunoprecipitated with control IgG or AGO2 antibody and
gene enrichment fold changes were measured by real-time qRT-PCR. Hprt was used for normalization and Gapdh was used as a negative control.
(legend continued on next page)
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the transcriptome. We uncovered one such mechanism as
described below.
We considered transcripts that show strong targeting by
miRNAs, as defined by those sites withR100 reads in the PAR-
CLIP data set. Among the 3,033 sites, a significant fraction
show increased expression in Elavl1 KO cells when miRNA and
ELAVL1 binding sites are close to each other. Previous studies,
which examined ELAVL1 interaction with select mRNAs, sug-
gested that RBP binding to mRNAs can have both positive and
negative effects on miRNA-mediated gene suppression. Indeed,
manyof themiRNAbindingsites that showalterations in response
to ELAVL1 levels contain proximal binding sites for the RBP (see
examples such as c-Myc). Interestingly, the fluctuations inmiRNA
binding to thesesitesweremuchhigher inmagnitude than thecor-
responding changes in expression of the corresponding mRNAs.
Nevertheless, increased miRNA binding is associated generally
withdecreasedexpressionofmRNAs. Thus, ELAVL1antagonizes
miRNA-mediated suppression of macrophage gene expression.
Our data set has been implemented in the genome browser in
a searchable format (http://genome.ucsc.edu/cgi-bin/hgTracks?
hgS_doOtherUser=submit&hgS_otherUserName=Yi%2DChien
%20Lu&hgS_otherUserSessionName=Ago2%20PARLIP%20and
%20mRNAseq), which provides a resource and should facili-
tate further studies on posttranscriptional gene regulation in
macrophages.
Macrophage Genes Involved in Vascular Development
and Angiogenesis Are Targeted by miRNAs and
Modulated by ELAVL1
Significant numbers of BMDM mRNAs that show high miRNA
binding regulate the process of vascular development/angio-
genesis. These processes are involved in key biological pro-
cesses such as wound healing as well as in disease processes
such as tumor angiogenesis and chronic inflammatory diseases.
Indeed, macrophages are critical for vascular network formation
during development because they chaperone filopodia-contain-
ing ‘‘tip’’ cells from vascular sprouts and allow them to fuse
together to form a primary vascular network (Fantin et al.,
2013). Our data suggest that miRNA-mediated gene regulation
is an important mechanism regulating macrophage regulation
of blood vessel formation and morphogenesis, consistent with
recent studies (Chang et al., 2013; Zhang et al., 2012). Because
macrophage functions have been implicated in angiogenic
switch of tumors (Ruffell et al., 2012) and tumor resistance to
antiangiogenic drugs and metastasis (De Palma and Lewis,
2013), molecular targets identified in this work can be tested
for their requirement in these processes.
Further analysis of transcripts targeted by miRNAs and the
subset that shows sensitivity to ELAVL1 levels revealed coordi-
nate regulation of several cellular processes, such as chemo-
taxis/cell migration, paracrine interaction with vascular cells,(E) The protein expression of ITGA4, CAV1, and MEF2A in WT and Elavl1 KO BM
(bottom) were shown. The value was expressed as the mean ratio to GAPDH ex
(F) miR-142-3p regulates CAV1 and MEF2A protein expression in BMDMs. Cells
antagomiR and protein lysates were immunoblotted with CAV1, MEF2A and GA
analysis (bottom) were shown. The value was expressed as the mean ratio to G
values were determined by Student’s t test. *p < 0.05, **p < 0.01.
Cell Reand signal transduction and gene transcription. This work pro-
vides a firm foundation to further investigate how the miRNA
network is regulated in complex processes such as angiogen-
esis and inflammation. Previous work has shown that
macrophage phenotype switch, for example, the so called ‘‘M2
phenotype,’’ is important in angiogenic switch and metastasis
(De Palma and Lewis, 2013; Ruffell et al., 2012). It will be of inter-
est to determine if the miRNAs identified in this work are altered
during the phenotype switch of macrophages.
Identification of a miRNA-Regulated Synchronized
Expression of ELAVL1 and ZFP36
We identified a major miRNA-targeted site in the 30 UTR of the
mRNA for ZFP36 (tristeraspolin/TTP), a major RNA binding pro-
tein that induces destabilization of ARE-containing mRNAs
(Blackshear et al., 2003). This site was predicted as the target
of miR-27 and ELAVL1, suggesting the competitive interaction
of ELAVL1 and miR-27 to regulate Zfp36 mRNA. Both ELAVL1
and ZFP36 are ARE-binding proteins that interact with similar
cis-acting sequences on mRNAs. However, in contrast to
ELAVL1, which is located primarily in the nucleus, ZFP36 is cyto-
plasmic. Indeed, the inducible prostaglandin synthase (Ptgs2
mRNA) and the oncogene (c-Myc mRNA) are both reciprocally
regulated by ZFP36 and ELAVL1 (Rounbehler et al., 2012). Our
data reveal a previously unrecognized miRNA-mediated regula-
tory system, whereby the levels of RNA stability and instability
factors are synchronized. When ELAVL1 levels are reduced,
miR-27-mediated suppression of ZFP36 is enhanced, thereby
reducing the levels of this RNA instability factor. This mechanism
may account, at least in part, for our observation that, under
steady-state conditions, the transcriptome of WT and Elavl1
KO cells is largely similar.
In summary, this work reports the comprehensive mapping of
miRNA binding sites in BMDMs, an important innate immune cell
type. Further, our data set also describes the miRNA binding
sites that are modulated by ELAVL1, a major RBP that regulates
gene expression by interacting with ARE and UREs. Moreover,
we provide evidence for coordinated miRNA targeting of tran-
scripts that regulate blood vessel development and angiogen-
esis. In addition, analysis of this data set identified miRNA-medi-
ated coordination of expression of ELAVL1 and ZFP36, two
major RBPs that induce or suppress gene expression, respec-
tively. This resource should allow further interrogation of macro-
phage posttranscriptional gene regulatory mechanisms in
vascular biology, immunology, and tumor biology.
EXPERIMENTAL PROCEDURES
Animals
Myeloid specific deletion of Elavl1 in C57Bl/6 mice was generated by crossing
Elavl1-floxed mice (Ghosh et al., 2009) with mice expressing Cre recombinase
driven by the lysozyme M promoter. All animal care and experimentalDMs. The representative immunoblot image (top) and densitometry analysis
pression of five independent experiments.
were transfected with 50 nM of control mimic, miR-142-3p mimic, or miR-142
PDH antibody. The representative immunoblot image (top) and densitometry
APDH expression of five independent experiments. All error bars show SD. p
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Figure 7. Loss of ELAVL1 Suppresses the Synthesis of ZFP36 Polypeptide
(A) miRNA binding sites from PAR-CLIP data set and mRNA expression levels for the Zfp36 gene is indicated on the USCS genome browser screen shot. The
labeling is the same as Figures 3 and 6 (above); actual ZFP36 binding sites from previous PAR-CLIP in human HEK293 cell are indicated with purple bars.
(B) Visualization of individual miRNA binding sites with the T-to-C conversion density estimate (red line) and read counts (gray bar) of the strongest PAR-CLIP
signal area within the Zfp36 30 UTRs. Predicted miRNA:mRNA alignment for miR-27a and miR-27b is listed below.
(legend continued on next page)
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protocols were conducted following the guidelines of the institutional care and
use committee of Weill Cornell Medical College.
Cell Culture
HEK293T cell lines were maintained in DMEM growth medium containing
high glucose (4.5 g/l) (Sigma), L-glutamine, and 10% fetal bovine serum
(Invitrogen). Cells were cultured at 37C in a humidified atmosphere containing
5% CO2.
BMDM Culture and PAR-CLIP
Animals were sacrificed using carbon dioxide, and bone marrow cells from
mouse femur and tibia were collected by flushing through PBSwith a 23-gauge
needle. Bonemarrow cells were cultured in one 150mmPetri disheswith com-
plete DMEM and 20% of L929 cell-culture medium for 6 days (Weischenfeldt
and Porse, 2008). BMDMs for transfection and sequencing library preparation
were thenwashed twicewith PBS and cultured in complete DMEMwith 20%of
L929 cell-culture medium over night and harvested with 0.2 mM EDTA in PBS.
PAR-CLIP protocol for BMDMs was described previously (Hafner et al.,
2010a, 2010b) with several minor described in Supplemental Experimental
Procedures.
PARalyzer Annotation and miRNA Target Sites Predication
For WT and ELAVL1 KO PAR-CLIP library, PARalyzer was used to identify
binding sites as described previously (Corcoran et al., 2011). Detail analysis
methods are described in Supplemental Experimental Procedures. Clusters
that overlappedwith predicted miRNA binding site from Target Scan database
(TargetScan 6.2, mouse nonconserved and conserved predictions) were iden-
tified using custom scripts. Customized miRNA prediction procedure and
signal-to-noise calculation method on Figure 3A are further described in Sup-
plemental Information.
Total RNA Isolation, miRNA Isolation, and High-Throughput
Sequencing for mRNA or miRNA
Total RNA and small RNAswere isolated as detailed in themanufacturer’s pro-
tocols (Clontech), and RNA quality was checked by an Agilent 2100 Bio-
analyzer (Agilent Technologies). Small RNA and mRNA libraries preparation
were followed as manufacturer’s protocols (Illumina Small RNA v1.5 Sample
Preparation Kit and Illumina mRNA sequencing Sample Preparation Kit, Illu-
mina). All libraries were sequenced for single reads, 42 cycles on the Illumina
Genome Analyzer IIx (Illumina). Detailed protocol for sequencing data analysis
is further described in Supplemental Information.
Real-Time Quantitative RT-PCR Analysis for miRNAs and mRNAs
Total miRNA was subject to poly(A) tailing reaction and reverse transcribed
with oligo-dT adaptor primer (qScript miRNA cDNA synthesis kit, Quanta)
and followed by quantitative PCR (qPCR) amplification with the specific
miRNA sequence primer and oligo-dT adaptor sequence primer (PerfeCTa
SYBR Green system, Quanta). Expression of specific miRNAs was normalized
to the value of U6 small nuclear RNA. To validate mRNA expression by real-(C) Effect of Elavl1 deletion on miRNA binding with Zfp36 mRNA. WT or Elavl1 K
antibody. Zfp36 mRNA physically associated with the AGO2 complex was quan
(D) Western blot analysis of ZFP36 polypeptide levels in control or miR-27b mimic
show a representative experiment that was repeated three times. Densitometry
(E) Western blot analysis of ZFP36 polypeptide levels in WT and Elavl1 KO BMD
repeated at least three times. Densitometry analysis of ZFP36 expression levels
p values were determined by Student’s t test. *p < 0.05, **p < 0.01.
(F) Schematic of different mutation sites on the Zfp36 30 UTR construct in a dual
(G) Luciferase reporter containing WT or mutated 30 UTR of Zfp36 was transfecte
miR-27b mimic in a dose-dependent manner was quantified. For each 30 UTR, re
calculated relative luciferase activity of each 30 UTR reporter was further normal
(H) HEK293T cells expressing control or Elavl1 shRNA were transfected with lu
efficiency of Elavl1 with shRNA (90%) was confirmed by an immunoblot analys
miR-27b mimic in both cell lines, and reporter activity was determined (n = 3). All
0.05, **p < 0.01.
Cell Retime qRT-PCR, RNAwas reverse transcribedwithMMLV reverse transcriptase
(Invitrogen), and cDNAs were amplified with specific primers (primer bank) us-
ing SYBR green master mix (PerfeCTa SYBR Green system, Quanta).
GO Analysis
Genes with high PAR-CLIP signals at 30 UTR (R200 reads in WT or Elavl1 KO)
were performed for Gene Ontology analysis by using DAVID Bioinformatics
program (Huang et al., 2009a, 2009b). The expressed genes from mRNA
sequencing data set (R0.1 RPKM) were used as a background for this
analysis.
Luciferase miRNA Target Reporter Assay
Zfp36 30 UTR fragment (762 bp) was cloned into the pmirGLO vector (Prom-
ega). Mutations were made in the seed region of miR-27b binding site, ARE1
binding site, and ARE2 binding site. Detail primer sequences are described
in Supplemental Information.
HEK293T cells were cotransfectedwith 50 ng/ml pmirGLO vector containing
Zfp36 30 UTR (WT or mutant) miR-27b mimic (0–40 nM) (Thermo Scientific) us-
ing Lipofectamine-2000 (Invitrogen). After 40 hr, the cells were lysed, and lucif-
erase activity was measured using a luminometer. Firefly luciferase values
were normalized with renilla luciferase values.
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The sequencing data have been deposited in the GEO database under the
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